Our Services
Medical Information
Helpful Resources
Published on: 4/24/2026
Rybelsus slows gastrointestinal transit to improve blood sugar control and weight loss, but this mechanism can cause constipation by delaying gastric emptying, reducing intestinal motility and increasing fluid absorption from stool. Most patients find relief through hydration, gradual fiber increases, regular exercise, consistent toileting routines and short courses of over the counter stool softeners or laxatives.
If constipation persists despite these measures, leads to complications or significantly affects quality of life, you and your healthcare provider may discuss alternative diabetes medications; see below for critical details on when to switch therapies and what options to consider.
Rybelsus (oral semaglutide) is a popular medication for type 2 diabetes that works by mimicking the gut hormone GLP-1 (glucagon-like peptide-1). It helps lower blood glucose and often promotes weight loss. However, like many medications that act on the digestive system, it can lead to gastrointestinal side effects—including constipation. This article explains why Rybelsus can cause constipation, how common it is, practical steps to manage it, and when you might consider switching to another therapy.
Rybelsus is the first FDA-approved oral version of a GLP-1 receptor agonist. GLP-1 is a natural hormone that:
These combined effects help patients achieve better glycemic control and often contribute to weight loss. Yet the slowing of digestive processes is a double-edged sword: it can be great for blood glucose but may also disrupt normal bowel movements.
When patients ask "why does Rybelsus cause constipation?" they're really asking how the drug's beneficial actions on blood sugar end up affecting regularity. Key mechanisms include:
Delayed gastric emptying
Semaglutide slows how quickly food leaves the stomach. This delay can ripple through the rest of the digestive tract, reducing movement (motility) in the intestines.
Reduced intestinal motility
GLP-1 receptor activation in the gut decreases smooth muscle contractions in both the small and large intestines. With slower transit, stool can become harder and drier.
Fluid absorption changes
More time in the colon allows water to be reabsorbed from stool, making it firmer and more difficult to pass.
Dietary shifts
Many people on Rybelsus eat less (due to reduced appetite). If fiber and fluid intake drop, that alone can trigger or worsen constipation.
Individual variability
Genetics, baseline bowel habits, other medications and medical conditions can all influence how strongly someone feels this side effect.
Understanding these factors helps explain why constipation is a known but manageable side effect of Rybelsus.
Clinical trials and real-world data indicate:
While it's not the most common GI side effect (nausea, vomiting and diarrhea tend to rank higher), constipation can be persistent and bothersome for some.
If you're taking Rybelsus and notice harder stools or less frequent bowel movements, consider these strategies before switching medications:
Hydrate well
Increase fiber gradually
Exercise regularly
Establish a routine
Use over-the-counter aids when needed
Mind your other medications
Most people find that a combination of these measures relieves mild to moderate constipation within 1–2 weeks.
Constipation alone isn't always a reason to change therapy. But you may discuss alternatives with your doctor if:
Be sure to weigh the benefits of Rybelsus (excellent blood sugar control, weight loss, cardiovascular protection) against the downsides. For many, optimizing bowel management solves the problem without giving up the drug.
If you and your doctor decide that Rybelsus isn't the right fit, potential alternatives include:
Other GLP-1 receptor agonists (e.g., injectable semaglutide, dulaglutide)
– May have similar GI effects but differ in dosing schedule.
DPP-4 inhibitors (e.g., sitagliptin, saxagliptin)
– Generally well tolerated in terms of GI side effects, though less potent weight loss.
SGLT2 inhibitors (e.g., empagliflozin, canagliflozin)
– Promote glucose excretion in urine; possible urinary/genital infections but minimal constipation risk.
Metformin
– First-line therapy; can cause diarrhea more than constipation, but dosing adjustments can help.
Insulin
– Powerful glucose-lowering, but requires injections and carries a risk of hypoglycemia.
Each class has its own pros and cons. A personalized approach—considering your glycemic targets, weight goals, risks and preferences—is key.
If you're experiencing persistent digestive issues or aren't sure whether your symptoms are typical, try Ubie's free AI-powered Constipation symptom checker to get personalized insights and guidance on whether you should seek medical care.
Constipation is common and often benign, but certain "red flags" warrant prompt evaluation:
If you experience any of these, contact your healthcare provider immediately or seek emergency care.
Constipation with Rybelsus stems largely from its intended effect of slowing gastrointestinal transit. Most patients find relief through diet, hydration, exercise and mild laxatives. Only when symptoms remain severe or affect quality of life should you and your doctor consider switching to a different diabetes medication.
Always keep an open line of communication with your healthcare team. If you notice any worrying symptoms or if constipation becomes unmanageable, speak to a doctor promptly—especially if you experience pain, bleeding or signs of obstruction. Your safety and comfort matter, and there are many effective options to help you manage both diabetes and digestive health.
(References)
* Blüher, M., et al. "Oral Semaglutide: A Narrative Review of Its Efficacy and Safety in Patients with Type 2 Diabetes." *Diabetes Therapy*, 2021. 12(9): 2383–2394. PMID: 34509995.
* Singh, S., et al. "Gastrointestinal Tolerability of Oral Semaglutide in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis." *Diabetes Therapy*, 2021. 12(7): 1851–1867. PMID: 34185121.
* Wilding, J.P.H., et al. "Managing the gastrointestinal side effects of GLP-1 receptor agonists in clinical practice." *Diabetes, Obesity and Metabolism*, 2021. 23 Suppl 1: 18-28. PMID: 33241695.
* Jendle, J., et al. "Oral Semaglutide: A Review of Its Clinical Efficacy and Safety." *Drugs*, 2022. 82(2): 161–178. PMID: 35050478.
* Park, J.H., et al. "Oral Semaglutide: Patient Experiences and Perspectives on Treatment for Type 2 Diabetes." *Diabetes Therapy*, 2023. 14(10): 1735–1749. PMID: 37624641.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.